EMEA-002997-PIP02-22 - paediatric investigation plan

Latozinemab

Key facts

• Active Substance:
  Latozinemab
• Therapeutic area:
  Neurology
• Decision number:
  P/0146/2022
• PIP number:
  EMEA-002997-PIP02-22
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of amyotrophic lateral sclerosis
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  Alector, Inc.

  E-mail: [e-mail]; Tel: [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  13/05/2022

Decision

P/0146/2022 : EMA decision of 13 May 2022 on the granting of a product specific waiver for latozinemab (EMEA-002997-PIP02-22)

AdoptedReference Number: EMA/206559/2022